Triomics is a San Francisco-based start-up that has developed an artificial intelligence (AI) platform aimed at helping cancer specialists identify the best clinical trials and treatments for their patients more efficiently. With $15 million in new funding, Triomics aims to address the time-consuming process of manually searching through patient records to match them to trials and emerging treatments. The platform uses large language models (LLMs) to automate this process, achieving a 95% accuracy rate in matching patients to trials and treatments in a matter of minutes. This technology not only saves time for oncologists but also improves patient access to potentially life-saving treatments.
The platform developed by Triomics has applications beyond cancer treatment, offering healthcare providers the ability to automate various manual processes such as quality assurance and clinical pathway tracking. However, the company’s primary focus is on improving patient access to trials and treatments, as highlighted by the positive feedback from early adopters like Anai Kothari, a surgical oncologist at the Medical College of Wisconsin Cancer Center. By quickly and accurately converting complex cancer data into actionable information, Triomics aims to enhance patient care outcomes and streamline healthcare workflows.
Triomics’ success since its launch in 2020 can be attributed to its strategic approach of bringing together expertise in AI research and clinical oncology. By merging the skills of AI researchers specializing in customizing language models with clinical staff with oncology-specific experience, the company has been able to develop a platform that meets the unique needs of cancer patients and healthcare providers. With a team of around 50 specialists, Triomics plans to expand its workforce to around 60 employees in the near future to support its growth and commercialization efforts.
The company has already formed partnerships with several hospital and healthcare institutions and aims to onboard up to 15 institutions by the end of the year. Investors such as Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator are optimistic about Triomics’ potential for success, citing its use of existing healthcare datasets and generative AI to automate clinical trials and streamline cancer center workflows. The company’s proprietary oncology-specific LLMs and partnerships with leading cancer care and research centers position it well to deliver significant value to cancer care providers and patients in the US and globally.
Through its innovative AI platform, Triomics is poised to revolutionize the way cancer specialists identify and match patients to clinical trials and treatments. By automating the data processing and analysis that typically require manual intervention, the company aims to improve patient outcomes by enhancing access to potentially life-saving treatments. The success of Triomics can be attributed to its strategic approach of combining expertise in AI research and clinical oncology, allowing the company to develop a platform that meets the unique needs of cancer patients and healthcare providers. With a growing number of partnerships and investors backing its efforts, Triomics is well-positioned to continue making strides in the field of cancer care and research.